Mitsubishi Tanabe Pharma America Inc (MTPA), a subsidiary of Japan-based Mitsubishi Tanabe Pharma Corporation (MTPC), announced on Monday that it has changed its corporate name to Tanabe Pharma America Inc (TPA), effective immediately.
In July, MTPC said that it would change name to Tanabe Pharma Corporation, effective 1 December 2025, following its acquisition by private investment firm Bain Capital.
TPA will continue to pursue a robust pipeline of products for hard-to-treat diseases, including neurodegenerative diseases, inflammatory, and metabolic conditions, the company said.
AbbVie receives positive CHMP opinion for upadacitinib in severe alopecia areata
Evommune reports Phase 2b trial miss for EVO756 in chronic spontaneous urticaria
AbbVie receives positive CHMP opinion for upadacitinib in non‑segmental vitiligo
NeuroSense reports Phase 2 proof-of-concept study results for PrimeC in Alzheimer's Disease
Vascarta announces VAS-101 Phase I results in sickle cell disease patients
Cirius Therapeutics commences enrolment and dosing for Phase 2 study of CIR-0602K in type 1 diabetes
Kither Biotech completes Phase 1 KIT2014 clinical study
Gesynta Pharma reports progress in Phase 2 trial of vipoglanstat
Hillhurst Bio reports first subject dosed in Phase 2a trial of HBI-002 for Parkinson's disease
Organon secures FDA approval expanding TOFIDENCE indications for CRS and paediatric COVID-19
Sanofi halts phase 3 MOBILIZE study of riliprubart in CIDP
Lynk Pharmaceuticals' partner Formation Bio doses first participant in BLKR201 Phase 1 trial
FDA grants rare paediatric disease designation to RedHill's opaganib
Antengene presents first ATG-207 preclinical data at EULAR 2026